Zhifei Biotech (300122.SZ): Pandemic influenza virus mRNA vaccine clinical trial application accepted

Zhitong Finance App News, Zhifei Biotech (300122.SZ) issued an announcement. The company recently learned that the pandemic influenza virus mRNA vaccine developed by its wholly-owned subsidiary Anhui Zhifeilong Koma Biopharmaceutical Co., Ltd. (hereinafter referred to as “Zhifeilong Koma”) has obtained the State Drug Administration's Drug Clinical Trial Application Acceptance Notice (acceptance number: CXSL2601222). If no negative or questioning opinions have been received from the Drug Review Center within 60 days from the date of acceptance, Zhifeilong Koma may conduct clinical trials according to the submitted plan.

The pandemic influenza virus mRNA vaccine developed by SmartFeilong Koma is intended to be used to vaccinate against pandemic influenza. By receiving this vaccine, the body can be stimulated to develop immunity against the influenza pandemic virus. This product is developed based on the company's self-established mRNA technology platform and has the advantage of rapid response. Compared with traditional chicken embryo inactivation vaccines, the mRNA vaccine preparation cycle is significantly shortened.